$1.03
8.85% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US0070251097
Symbol
ADTX

Aditx Therapeutics Inc Stock price

$1.03
-0.16 13.45% 1M
-21.77 95.48% 6M
-46.42 97.83% YTD
-10,898.97 99.99% 1Y
-3,491,998.97 100.00% 3Y
-93,799,998.97 100.00% 5Y
-101,199,998.97 100.00% 10Y
-101,199,998.97 100.00% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.10 8.85%
ISIN
US0070251097
Symbol
ADTX
Industry

Key metrics

Basic
Market capitalization
$2.5m
Enterprise Value
$5.1m
Net debt
$2.6m
Cash
$480.0k
Shares outstanding
1.2m
Valuation (TTM | estimate)
P/E
negative | 0.0
P/S
41.7 | 0.1
EV/Sales
85.6 | 0.3
EV/FCF
negative
P/B
0.2
Financial Health
Equity Ratio
27.6%
Return on Equity
-455.0%
ROCE
-136.8%
ROIC
-
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
$60.0k | $21.3m
EBITDA
$-21.4m | -
EBIT
$-21.9m | $-9.2m
Net Income
$-31.3m | $-306.1m
Free Cash Flow
$-22.5m
Growth (TTM | estimate)
Revenue
-88.2% | 16,255.4%
EBITDA
31.6% | -
EBIT
31.0% | 66.9%
Net Income
24.4% | -658.6%
Free Cash Flow
-9.3%
Margin (TTM | estimate)
Gross
-917.0%
EBITDA
-38,686.1% | -
EBIT
-39,667.6%
Net
-56,662.0% | -1,439.6%
Free Cash Flow
-40,713.6%
More
EPS
$-44.5
FCF per Share
$-18.6
Short interest
5.1%
Employees
26
Rev per Employee
$10.0k
Show more

Is Aditx Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Aditx Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Aditx Therapeutics Inc forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Aditx Therapeutics Inc forecast:

Buy
75%
Hold
25%

Financial data from Aditx Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.06 0.06
88% 88%
100%
- Direct Costs 0.56 0.56
14% 14%
933%
-0.51 -0.51
292% 292%
-850%
- Selling and Administrative Expenses 17 17
2% 2%
29,133%
- Research and Development Expense 3.95 3.95
71% 71%
6,583%
-21 -21
32% 32%
-35,650%
- Depreciation and Amortization 0.54 0.54
2% 2%
900%
EBIT (Operating Income) EBIT -22 -22
31% 31%
-36,560%
Net Profit -31 -31
24% 24%
-52,217%

In millions USD.

Don't miss a Thing! We will send you all news about Aditx Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aditx Therapeutics Inc Stock News

Neutral
Business Wire
2 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, announced today that it has signed a custody agreement with Crypto.com, a global leader in digital asset platforms, to establish a custodial crypto account. The agreement is a foundational step in the broader planne...
Neutral
PRNewsWire
8 days ago
SAN DIEGO , Aug. 5, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) is proud to announce that its CEO,  Saundra Pelletier , will be honored with the Trailblazing Female Founders Award at the 2025 STIMULATE Conference , the premier U.S. sexual wellness industry event. The award will be presented today,  August 5, 2025 , during the conference held in  Nashville, Tennessee.
Neutral
Business Wire
15 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc., (“Pearsanta”) has engaged Spartan Capital Securities, LLC (“Spartan”) as lead underwriter for its planned Initial Public Offering (”IPO”). This marks an importan...
More Aditx Therapeutics Inc News

Company Profile

ADiTx Therapeutics, Inc. is a preclinical stage, life sciences company which engages in the development of nucleic acid (DNA)-based technologies to minimize rejection of transplanted organs by human recipients as well as address autoimmune diseases and allergies. The firm have worldwide license for commercializing a nucleic acid-based technology, named Apoptotic DNA Immunotherapy (ADi), which utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissue. The company was founded by Leonard L. Bailey, Shahrokh Shabahang, and Amro Albanna on September 28, 2017 and is headquartered in Loma Linda, CA.

Head office United States
CEO Amro Albanna
Employees 26
Founded 2017
Website aditxt.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today